The effectiveness of the one-step combined laser technique, consisting of the modified selective laser activation of the trabecula (MSLAT) and Descemet's goniopuncture (DGP)

Session Details

Session Title: Presented Poster Session: Glaucoma II

Venue: Poster Village: Pod 3

First Author: : T.Lyubimova RUSSIA

Co Author(s): :    E. Tumanyan   E. Ivashchenko                    

Abstract Details

Purpose:

To evaluate the effectiveness of the one-step MSLAT and DGP in severe surgically-operated POAG patients with a significant pigmentation of the TM of the anterior chamber angle (ACA),  pseudoexfoliation (PEX) syndrome and non-normalized ophthalmotonus.

Setting:

S.N. FEDOROV NMRC "MNTK "EYE MICROSURGERY"

Methods:

We examined 150 patients (150 eyes) with severe surgically-operated POAG in whom we observed IOP increase up to 26.3±4.7 mm Hg during 9.5 ± 2.2 months afternonpenetrating deep sclerectomy (NDSE) with a significant pigmentation of the TM of the ACA and PEX syndrome. The investigation group included 95 patients (95 eyes) who underwent a one-step MSLAT with DGP, the control – 55 patients (55 eyes) who underwent DGP alone. The follow-up period was 3 years.

Results:

In the main group, the IOP was compensated up to 1 year, when hypertensive monotherapy was first administered to 11.6% of patients, by the end of the 3rd year – in 17.5%. In 22% of patients we couldn't reach the IOP compensation and performed an additional NDSE by the end 3rd year. In control the IOP stayed compensated without therapy only 3rd-6th month. By the end of the 3rd years the percentage of patients with monotherapy 25.4%. In 61.7% we performed an additional NDSE by the end of the 3rd year due to the elevation of IOP despite hypotensive therapy.

Conclusions:

The combined laser surgery in the eyes with severe surgically-operated POAG, including one-step DGP and SLAT, is more effective in comparisson with the classical DGP. It is proved by the stable and prolonged hypotensive effect without any additional therapy and a lower percentage of surgical re-intervention.

Financial Disclosure:

... gains financially from competing product or procedure, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... is employed by a competing company, ... has significant investment interest in a company producing, developing or supplying product or procedure presented